Scribe Therapeutics Achieves Second Success Milestone for In Vivo CRISPR Program with Eli Lilly

Published Friday, June 26, 2026 · 8:27 PM EDT

Scribe Therapeutics announced it achieved a second success milestone under its collaboration with Eli Lilly and Company. The milestone applies to one of the targets in the companies' program to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseases. The achievement is the second such event in the partnership. It follows an initial milestone and a joint scientific presentation at ASGCT in 2025. The collaboration was announced in 2023. Scribe said the milestone validates its technologies and strengthens momentum across its genetic medicine portfolio. Under the agreement, Scribe is eligible to receive more than 1.5 billion dollars across all programs in milestone payments for research, development, regulatory, and commercial achievements, as well as low-double-digit royalties. Benjamin Oakes, co-founder and chief executive officer of Scribe, said the milestone reflects strong execution and continued validation of the company's in vivo CRISPR technologies by a partner with deep technical and clinical rigor. He added that advancing the program reinforces the company's conviction that purpose-built CRISPR technologies can clear the potency and specificity thresholds required for transformative therapies in neurological and neuromuscular diseases. Svetlana Lucas, chief business officer at Scribe, said the achievement further advances a productive collaboration with Lilly.

Sources

Scribe Therapeutics

Published by Tech & Business, a media brand covering technology and business. This story was sourced from Scribe Therapeutics and reviewed by the T&B editorial agent team.

Back to Newswire

Keep reading

Full wire

Capital Products

U.S. Series A funding reaches $42 billion as deal counts hold steady

U.S. startups raised $42 billion in Series A funding through October 2026, up roughly 60% year over year, while deal counts remained on pace with recent years, Crunchbase data shows.

Products

Ardian raises €1 billion for European semiconductor investment platform

Ardian has raised €1 billion for its debut semiconductor investment platform, including nearly €700 million ($781 million) in fund commitments alongside co-investments, according to a statement reviewed by Bloomberg.

Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.

Ingenix claims biological reasoning benchmark lead, announces open-source version

Ingenix says its 9-billion-parameter Thalamus Reasoning model ranks first among 29 models on LongevityBench, which tests language models on cellular aging research.